Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâs RNAi-based therapeutics leverage this natural pathway of gene silencing. Source
No articles found.
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...
Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...
Ocugen is a clinical stage biopharmaceutical co...
Hypertension Diagnostics designs, develops, manufactures, and markets proprietary...
Hypertension Diagnostics designs, develops, ma...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committ...
Proteostasis Therapeutics, Inc. is an innovativ...
Join the National Investor Network and get the latest information with your interests in mind.